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The major histocompatibility complex (MHC) class II is involved both in thymocyte matura-
tion and peptide presentation and might thus play a key role in the pathogenesis of paraneo-
plastic myasthenia gravis (MG) in thymomas. To further investigate this issue, we analyzed
and scored the expression of epithelial class II expression in 35 thymomas (medullary, MDT;
mixed, MXT; cortical and well differentiated thymic carcinoma, CT WDTC) and correlated
it with the histological tumor subtype, prevalence ofMG and thymocyte maturation, which
was analyzed by flow cytometry and RT-PCR. Our results show that both MHC class II
expression and thymocyte maturation are highly dependent on the histological tumor subtype.
CT WDTC retain features of the normal outer thymic cortex, namely substantial MHC class
II expression together with normal early thymocyte maturation until late phases of positive
selection, but disturbed terminal thymopoiesis. By contrast, MDT and MXT retain features of
the normal inner cortex and the medulla with low to absent class II expression and highly
abnormal early thymocyte maturation including impaired positive selection, while terminal T
cell maturation in MXT appeared undisturbed. There was no correlation between MHC class
II expression andMG status for a given tumor subtype. In conclusion, our results provide evi-
dence for a different histogenesis of cortical thymomas and well differentiated carcinomas on
the one hand and mixed and medullary thymomas on the other.
Decreased expression levels ofMHC class II, although of crucial importance for abnormal
intratumorous maturation, are not sufficient to explain the emergence of paraneoplastic MG.
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INTRODUCTION
Myasthenia gravis (MG) is a neurological disorder
characterized by autoantibodies against the acetylcho-
line receptors at the neuromuscular junction, resulting
in generalized muscle weakness. The clinical presen-
tation of MG is almost invariably associated with
pathological alterations of the thymus (Marx et al.
1997). About 10 % ofMG cases are related to thymic
epithelial tumors (thymomas), which have been sub-
divided into medullary (MDT), mixed (MXT) and
cortical thymomas (CT) and well differentiated
thymic carcinomas (WDTC) based on the morpholog-
ical resemblance of the neoplastic to normal thymic
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epithelium (Kirchner et al. 1992, Mtiller-Hermelink et
al. 1994).
Thymomas characteristically retain organotypic
features of the normal thymus, especially the capacity
to generate mature T cells. Thus, a maintained but
non-tolerogenic intratumorous thymopoiesis plus
export of mature T cells from thymomas to peripheral
lymphoid organs have been proposed to be a prerequi-
site for the development of paraneoplastic MG
(Mtiller-Hermelink et al. 1997). However, although
thymomas have been shown to be enriched in autore-
active T cells (Sommer et al. 1990; Nenninger 1998,
Schultz 1999), the molecular basis of autoimmuniza-
tion by thymomas remains largely enigmatic.
In recent years, some consistent features of these
tumors have been described, including 1) intratumor-
ous overexpression of autoantigen related epitopes
(Mygland et al. 1997; Wilisch et al. 1997, Schultz et
al. 1999) and 2) impaired intratumorous thymopoie-
sis, particularly of the CD4 lineage (Takeuchi 1995;
Nenninger 1997, 1998). Cells maturing in the thymus
pass two critical checkpoints, positive and negative
selection. During positive selection the thymic corti-
cal epithelium presents an evolutionary optimized set
of thymic peptides (Chan et al. 1993) bound to major
histocompatibility complex (MHC) class I and II mol-
ecules to immature thymocytes. Depending on the
MHC class recognized by the T cell receptor (TCR),
either CD4 or CD8 are engaged and help to further
increase the surface expression of the TCR and CD3
(Davis et al 1993). If the resulting avidity reaches a
threshold level, the cell receives a survival signal.
However, if the resulting avidity is too high, the cell is
eliminated through apoptosis, a mechanism termed
negative selection (Bevan 1997; Marrack and Kappler
1997; Williams et al. 1997; Jameson and Bevan
1998). Only cells surviving these two MHC-depend-
ent checkpoints are allowed to complete maturation
and leave the thymus (Janeway and Travers 1994).
Although the MHC is thus critically involved in both
thymocyte maturation and antigen presentation, it has
not been clarified whether abnormal MHC expression
levels are a consistent feature of thymomas (Willcox
et al. 1987, Takeuchi et al. 1995, Nenninger et al.
1997) and whether alterations of MHC levels are
related to abnormal thymopoiesis. Therefore we tried
to further dissect the role of this molecule in intratu-
morous thymocyte maturation and in the pathogenesis
of paraneoplastic MG.
RESULTS
Reduced Epithelial Expression ofMHC Class II
is a Consistent Feature of Thymomas, but Does
Not Correlate with the Presence or Absence
of Myasthenia Gravis
A reduced expression of epithelial HLA-DR at least
in a subset of MG-associated thymomas has been
described previously (van der Kwast 1985, Chilosi et
al. 1986, Willcox et al. 1987, Takeuchi et al. 1995,
Nenninger et al. 1997). However, there were no con-
clusive data on the prevalence and extent of this alter-
ation and its significance for autoimmunity. In this
study, we scored the expression of HLA-DR, DP, DQ
and invariant chain (li) semiquantitatively (0 to
3 points for negative, weak, intermediate and strong
staining intensity of each isotype), and calculated the
cumulative MHC class II expression level
(MHC-score) in a given case as the percentage of the
maximal possible score.
Compared with adjacent thymic remnants and con-
trol thymuses, in which the average MHC-score was
88,5 %, class II expression was reduced in all
instances regardless of the histological tumor subtype
in a series of 35 thymoma cases. However, class II
expression was lowest in those tumor types in which
the prevalence ofMG was lowest, namely medullary
(average MHC-score 4 %, prevalence ofMG 15,4 %)
and mixed thymomas (average MHC-score 0,96 %,
prevalence ofMG 56 %). On the other hand, class II
was significantly higher in those tumor types with
high prevalence of MG, namely cortical thymomas
and well differentiated thymic carcinomas (average
MHC-score in cortical thymomas 21,2 %; prevalence
ofMG 75,8 %; average MHC-score in well differenti-
ated thymic carcinomas 24,5 %; prevalence of MG
84,2 %) (Tab I). Within a thymoma subtype (e.g.
among cortical thymomas), there was no correlation
between the MHC-score and the presence or absenceDISTINCT MECHANISMS IN THE SHAPING OF MYASTHENIA GRAVIS-ASSOCIATED THYMOMAS 281
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FIGURE Intrapersonal comparison of median surface expression levels of CD4, CD8, CD3 and T cell receptor otl at different stages of
thymocyte maturation in thymomas (flow cytometry). Dots indicate the difference between the value of the thymoma and the residual thy-
mus of one individual patient. (4 mixed and 8 cortical thymomas well differentiated carcinomas, 12 residual thymuses). As there were no
statistically significant differences between mixed and cortical thymomas, all tumors were compared to the residual thymuses. In thymomas,
surface CD4 was significantly increased on immature, pre-selective thymocytes, while there was no alteration in the surface expression of
CD8, CD3 and the ct[ T cell receptor
ofMG. Of note, there were no differences in the stain-
ing intensity ofMHC class I isotypes between thymo-
mas and residual and control thymuses. These
findings are in good agreement with earlier reports on
reduced levels ofMHC class II, but not class I, in thy-
moma epithelial cell lines (Papadopoulos et al. 1989).
TABLE Histological subtypes and prevalence of myasthenia gravis in 164 thymoma cases and results of immunohistochemical analysis of
MHC class II isotypes in 35 cases with available frozen material
Thymoma type cases MG+ (%) IHC (MG+ /MG-) MHC-Ilpositive cases (MG+ /MG-)
medullary 13 2 (15,4) 5 (1 4) (0 1)
mixed 41 23 (56) 8 (3 5) (1 0)
cortical 91 69 (75,8) 10 (7 3) 5 (2 3)
well differentiated thymic carcinomas 19 16 (84,2) 12 (12 0) 7 (7 0)
MGI myasthenia gravis; IHC: cases available for immunohistochemical analysis of MHC class II isotypes, MHC-II positive cases (by
IHC): MHC-score > 0 %.282 E STROBEL et al.
Immature, Pre-Selective T Cells In Thymomas
Show Selective Upregulation of Surface CD4
CD4 plays a crucial role in positive selection by
enhancing the intrinsically low avidity of the TCR for
its ligands (Mc Carthy et al. 1988; Zuniga-Pflticker
1989; Dutz et al. 1995, Groves et al. 1997). In conse-
quence, any alteration of either the surface expression
ofMHC or the TCR that would affect the TCR:MHC
interaction would also require adjustment of the CD4
level in order to achieve a survival signal. Therefore,
we compared the median expression levels of CD4,
CD8, CD3 and the eta3 T cell receptor on different thy-
mocyte subsets in thymomas and residual thymuses
by flow cytometry (Fig. 1).
Corresponding to the highly decreased expression
ofMHC class II on epithelial cells, thymoma-derived
immature T cell populations of all histological tumor
subtypes showed a significant upshift of surface CD4
compared to cells derived from residual and control
thymuses. In particular, CD4 expression was signifi-
cantly increased on CD3-4+8-, CD3-4+8+ and
CD3+4+8+ cells, while this upshift was no longer
detectable on mature CD3+4+8- cells. The
MHC-class specifity oi: this alteration was underlined
by the fact that CD8 surface expression did not show
statistically significant alterations. Moreover, surface
levels of CD3 and TCRa[ were virtually identical in
thymomas and residual thymuses.
The Shaping of the Mature CD4 T Cell Repertoire
in Cortical Thymomas May Involve Other Factors
than in Mixed Thymomas
It has been previously reported that thymocyte matu-
ration in thymomas is quantitatively disturbed and
that numbers of mature CD4 cells are significantly
reduced, while the percentage of mature CD8 cells
remains unremarkable (Takeuchi et al. 1995, Nennin-
ger et al. 1997, Nenninger et al. 1998). As this con-
stellation seemed to be related to the reduced MHC
class II expression levels in thymomas, we tried to
correlate our findings on subtype-specific reduction
of class II with quantitative alterations in thymocyte
maturation, which were assessed by three-colour flow
cytometry. As the pathogenesis of MG in medullary
thymomas has been considered to be linked to the
particularly high numbers of recirculated T cells
found in these tumors (Nenninger et al. 1997), they
were not included in this study. In mixed thymomas,
MHC class II expression was generally completely
lost on the sensitivity level of immunohistochemistry.
Although these tumors displayed an abundant produc-
tion of immature CD3-4+8- and CD3-4+8+ precur-
sor cells as reported previously (Takeuchi et al. 1995,
Nenninger et al. 1997, Nenninger et al. 1998), most
cells apparently were not able to enter into positive
selection and were lost during transition into the
CD3+4+8+ stage (Fig. 2). This finding is in good
agreement with the particularly low levels of MHC
class II in these tumors, as T cell development is
known to be blocked at this stage also in the thymus
of MHC I II mice (Chan et al. 1993, Grusby et al.
1993) and in patients with MHC class II deficiency
(bare lymphocyte syndrome, BLS) (van Eggermond
et al. 1993). However, the few cells which entered
into positive selection seemed to complete maturation
towards the pre-emigrant stage successfully. This sug-
gests that positive selection might be the most impor-
tant single determinant in the shaping of the mature
thymocyte repertoire in mixed thymomas.
By contrast, cortical thymomas and well differenti-
ated thymic carcinomas in many cases expressed sub-
stantial amounts of variable class II isotypes.
Although positive selection was also impaired in CT /
WDTC, it seemed to be better preserved and the num-
bers of CD69+ cells were significantly higher than in
mixed thymomas. However, unlike in the normal thy-
mus and also in mixed thymomas, a major proportion
of these positively selected cells was eliminated
before reaching the pre-emigrant CD3+4+8- stage,
downsizing the frequency of CD3+4+8- cells to that
of mixed thymomas. Considering that epithelial MHC
class II is not required during terminal thymocyte
maturation (Vanhecke et al. 1997), our findings sug-
gest that factors independent of epithelial MHC class
II play a major and qualitatively abnormal role in the
shaping of the mature T cell repertoire in cortical thy-
momas and well differentiated carcinomas, but not in
mixed thymomas as compared to normal thymus.DISTINCT MECHANISMS IN THE SHAPING OF MYASTHENIA GRAVIS-ASSOCIATED THYMOMAS 283
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FIGURE 2 FACS analysis of main T cell subsets revealed significant differences in thymocyte maturation between mixed (MXT) and corti-
cal thymomas well differentiated carcinomas (CT WDTC). In mixed thymomas, the majority of cells was lost before entry into positive
selection, i.e. at the transition from the CD3-4+8+ to the CD3+4+8+ stage. However, the few positively selected (CD69+4+8+) cells in these
tumors seemed to reach the mature CD3+4+8- stage. In cortical thymomas and well differentiated carcinomas, the numbers of positively
selected cells were significantly decreased but still roughly comparable to residual and control thymuses (RT NT). However, most of these
cells were obviously eliminated before reaching the CD4 stage. Maturation of the CD8 lineage in all thymomas was undistinguishable from
control thymuses (not shown). (nd: not statistically different)
ReducedMHC Class II Expression in Thymomas
Does Not Skew the T Cell Receptor Repertoire
of Mature CD4 Cells
The interaction of the TCR with peptide / MHC class
II complexes has been reported recently to play a pre-
dominant role in the shaping of the mature TCR rep-
ertoire (Sant’Angelo et al. 1997). To investigate the
impact of reduced class II expression on the relative
frequencies of TCR VI gene usage, we applied
RT-PCR with a panel of 24 TCR VI family primers
on highly purified, mature CD4 cells isolated from
thymomas, residual thymuses and peripheral blood of
the same patients. Medullary thymomas were
excluded from this study for the same reasons as
stated above. The overall TCR repertoire was not
qualitatively affected neither in mixed nor in cortical
thymomas and was not significantly different from
residual thymuses and peripheral blood. Among the
most prevalent families were TCRV 5, 6, 8 and 13,
all of which have been reported to be the predominant
TCR VI3 segments also in normal (Baccala et al.
1991, Jores and Meo 1993) and non-neoplastic
MG-associated thymuses (Truffault et al. 1997; Nav-
aneetham et al. 1998). Minor, statistically non-signifi-
cant alterations in the peripheral blood were attributed
to confounding factors in this compartment, such as284 E STRI3BEL et al.
nonrandom homing to lymphatic tissues, different life
spans etc. (Jores and Meo 1993). The analysis of
CDR 3 length polymorphism did not reveal any dif-
ferences between thymomas and residual and control
thymuses. Thus, obviously neither intratumorous
clonal deletions nor expansions do occur, as inferred
from earlier studies based on TCR rearrangement
studies (Katzin et al. 1988; Tesch et al. 1989; Scarpa
et al. 1990).
DISCUSSION
In this paper, we tried to assess the effects of reduced
epithelial MHC class II on thymocyte maturation and
the development of paraneoplastic myasthenia gravis.
Our results show that reduced class II expression is a
general and consistent feature of thymomas. How-
ever, both the extent of this reduction and its effects
on thymocyte maturation appear to depend on the his-
tological thymoma subtype.
Unlike in other tumors, where downregulation of
MHC is a common finding with tumor progression
(Vegh et al. 1993; Lefebvre et al. 1999), class II
reduction was most pronounced in medullary and
mixed thymomas, which show a biologically benign
behaviour (Marx et al. 1999). Moreover, the selective
downregulation of class II isotypes pointed to one or
several defects in the pathways that regulate class II
expression, such as INF-7, STAT1 /IRF-1, or CIITA
(Darnell 1997; Piskurich et al. 1999) or any other of
the involved regulatory factors or, alternatively, over-
expression of suppressive factors, such as TGF-3
(Piskurich et al. 1999). At the same time, medullary
and mixed tumors show the lowest prevalence of
myasthenia gravis among all organotypic thymomas,
indicating that downregulation ofMHC class II per se
is not sufficient to explain the development of autoim-
munity.
The effects of reduced class II expression on thy-
mopoiesis seemed to be both qualitative and quantita-
tive. Although maturation of the CD4 lineage was
highly impaired, it was not altogether abrogated and
thymomas always contained substantial numbers of
phenotypically mature, pre-emigrant CD4 cells. This
finding was further confirmed by the fact that the T
cell receptor repertoire of highly purified pre-emi-
grant CD4 cells isolated from both mixed and cortical
thymomas and well differentiated carcinomas dis-
played the same restriction pattern as T cells isolated
from control thymuses.
In qualitative terms, upregulation of surface CD4
was equally observed in both mixed and cortical type
thymomas and suggested that immature thymocytes
indeed reacted to the altered microenvironment.
While CD4 seems to play only a minor role in posi-
tive selection in the presence of wild-type peptide
repertoires (Takahama et al. 1994a; van Bergen et al.
1998), it has great effects on the recognition of
altered, suboptimal ligands (Vignali and Strominger
1994, Madrenas et al. 1997, van Bergen et al. 1998).
Decreased MHC expression by itself may restrict the
wild-type self-peptide repertoire, as only dominant
peptide:MHC complexes are displayed, while minor
complexes fall below the threshold level required for
positive selection (Grubin et al. 1997) (Fig. 3). This
effect is the more important, as the self-peptide reper-
toire in thymomas is most probably biased and not
identical with the wild type repertoire (Mygland et al.
1997; Wilisch et al. 1997, Schultz et al. 1999). Upreg-
ulation of CD4 on maturing thymoctes in thymomas
might lead to the irregular positive selection of auto-
reactive precursors that would otherwise not have
received a survival signal. As the affinity required for
positive selection lies threefold below the affinity for
a signal inducing negative selection (Alam et al.
1996), it is conceivable that positively selected, auto-
reactive T cells might escape thymic deletion (Fig. 4).
In quantitative terms, reduction of class II expres-
sion corresponded with marked numerical alterations
of thymocyte subpopulations, again with sub-
type-specifc variations.
In mixed thymomas, the observed subtotal loss of
epithelial class II expression corresponded with a
strong reduction of thymocyte numbers between the
CD3-4+8+ and the CD4+8+69+ stage, indicating
impaired intitiation of positive selection in this tumor
type. Indeed, the capacity to induce positive selection
has been ascribed uniquely to MHC class II+ thymic
epithelial cells (Anderson et al. 1994 and 1999; ErnstDISTINCT MECHANISMS IN THE SHAPING OF MYASTHENIA GRAVIS-ASSOCIATED THYMOMAS 285
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FIGURE 3 Hypothetical impact of reduced epithelial class II expression on peptide presentation: only frequent peptides are displayed, while
minor peptides fall below the threshold level required for positive selection (Grubin et al. 1997). Moreover, due to overexpression of
tumor-related antigens, the peptide repertoire presented by epithelial cells in thymomas is most probably biased and not identical with the
wild-type repertoire
et al. 1996). However, MHC-independent factors,
such as TGF-, have also been reported to be
rate-limiting in the maturation of CD4+CD8+ thymo-
cytes in both mice (Takahama et al. 1994b, Plum et al.
1995) and humans (Mossalayi et al. 1995). Interest-
ingly, TGF-I3 has also been found to be involved in
negative regulation ofMHC class II (Lee et al. 1997;
Nandan et al. 1997). However, the few cells that
reached the CD4+8+69+ stage in mixed thymomas
seemed to complete maturation successfully, suggest-
ing that positive selection might be the most impor-
tant single determinant in the shaping of the mature
thymocyte repertoire in mixed thymomas.
By contrast, in line with the generally higher MHC
class II levels observed in cortical thymomas and well
differentiated thymic carcinomas, positive selection
seemed to be better preserved in these tumors and the
numbers of CD69+ cells were significantly higher
than in mixed thymomas. However, unlike in the nor-
mal thymus and also in mixed thymomas, a major
proportion of these positively selected cells was elim-
inated before reaching the pre-emigrant CD3+4+8-
stage, downsizing the frequency of CD3+4+8- cells to
that of mixed thymomas. We conclude from these
findings that the initiation of positive selection in thy-
momas is crucially dependent on the expression of
epithelial MHC class II. Although terminal matura-
tion seems to be possible in the absence of MHC
(Vanhecke et al. 1997), functional maturation still
requires an intact thymic microenvironment (Dyall
and Nikolic-Zigic 1995). Our findings thus suggest
that factors independent of epithelial MHC class II
play a major and qualitatively abnormal role in the
shaping of the mature T cell repertoire in cortical thy-286 E STROBEL et al.
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FIGURE 4 Potential selection advantage for pre-selection thymocytes with increased surface CD4 levels in thymomas with decreased MHC
class II expression. In a micromilieu with low epithelial class II levels, upregulation ofCD4 could convey a positively selecting signal, which
under normal conditions would lead to the elimination (negative selection) of the cell. As the affinity required for positive selection is well
below the affinity inducing negative selection, positively selected, autoreactive T cells might escape thymic deletion. Of note, CD4 upregu-
lation was measured as median surface level and thus only a subset in a given thymocyte population in thymomas showed this alteration
momas and well differentiated carcinomas, but proba-
bly not in mixed thymomas as compared to normal
thymus. Interestingly, we have previously reported on
an relative stromal overexpression of B7, a costimula-
tory molecule involved in negative selection (Kishim-
oto et al. 1996; Amsen and Kruisbeek 1996), in
cortical thymomas (Marx et al. 1994). Other factors
influencing the shaping of the CD4 lineage at the
post-selection stage could be the 1) action of dendritic
cells (Robey and Fowlkes 1994), 2) lack of
MHC-independent survival signals such as LFA 1 and
3 / ICAM (Jorgensen et al. 1996), or VCAM (Salo-
monet al. 1997), or 3) abnormally accelerated export
of mature T cells into the peripheral compartment.
In summary, bothMHC class II expression and thy-
mocyte maturation are highly dependent on the histo-
logical tumor subtype. CT / WDTC retain features of
the normal outer cortical epithelium, namely substan-
tial MHC class II expression together with unremark-
able thymocyte maturation until late phases of
positive selection. By contrast, MDT and MXT show
characteristics of the inner cortical / medullary epithe-
lium with low to absent class II expression (von Gau-
decker et al. 1986) and highly abnormal early
thymocyte maturation including impaired positive
selection, while terminal T cell maturation appears
undisturbed.DISTINCT MECHANISMS IN THE SHAPING OF MYASTHENIA GRAVIS-ASSOCIATED THYMOMAS 287
Our results thus provide further evidence for a dif-
ferent histogenesis of cortical thymomas and well dif-
ferentiated carcinomas on the one hand and mixed
and medullary thymomas on the other, as previously
inferred from morphological observations
(Mtiller-Hermelink et al. 1994).
While MHC class II expression and initiation of
positive selection may be the central factors in the
shaping of the T cell repertoire in mixed thymomas,
positive selection is better preserved in cortical thy-
momas and well differentiated thymic carcinomas and
additional, MHC-independent mechanisms seem to
be predominant in these tumors. However, even
heavy disturbances of thymocyte maturation and
selection do not involve the T cell receptor repertoire
of the few resulting pre-emigrant CD4 cells, at least
as far as V3 gene usage and CDR3 lenght polymor-
phism are concerned. Our failure to significantly cor-
relate MHC II levels with MG status suggests that
reduced epithelial MHC II expression by itself is not
sufficient to explain the emergence of paraneoplastic
myasthenia gravis.
MATERIALS & METHODS
Patients and Tumors
The tumors were subtyped according to the classifica-
tion of Mtiller-Hermelink and coworkers (Kirchner et
al. 1992; Mtiller-Hermelink et al. 1997). Cortical thy-
momas (CT) and well differentiated thymic carcino-
mas (WDTC), though morphologically distinct, are
closely related in functional terms (Nenninger et al.
1997, 1998; Schultz et al. 1999). Therefore, they were
considered as one group (CT / WDTC) to be com-
pared with mixed thymomas (MXT). The diagnosis of
MG was based on clinical findings and the detection
of anti-AChR autoantibodies in the patient’s serum.
Immunohistochemical Detection
and Semiquantitative Scoring ofMHC Class II
Isotypes
MHC class II epitopes were detected on frozen sec-
tions by a three-step immunoperoxidase technique as
described in detail previously (Kirchner et al. 1988).
The primary antibodies used were: L243 recognizing
a complex nonpolymorphic epitope on mature
HLA-DR dimers (Shackelford et al. 1983), Tti36 rec-
ognizing a complex epitope on mature and immature
(invariant chain (li)-associated) HLA-DR dimers and
Tia22 recognizing a monomorphic determinant on
HLA-DQ (Klohe et al. 1988). FA (B7/21) recognizes
a complex epitope on HLA-DP dimers (Klohe et al.
1988) and SD3 253.74 recognizes a simple C-termi-
nal epitope of the invariant chain (li) (amino acids
194-209) (Max et al. 1993). All primary antibodies
provided by Dr. H. Kalbacher, Institute of Physiologi-
cal Chemistry, Ttibingen, Germany). Epithelial cells
in thymomas and thymuses were identified using a
monoclonal antibody against cytokeratin 19, which is
known to be highly expressed in all subtypes of thy-
momas (Grommisch et al. 1997). Other MHC class II
expressing cell types, such as B cells, makrophages
and dendritic cells, were identified using monoclonal
antibodies against CD22 (Dako, Hamburg, Germany),
CD 16 (Dianova, Hamburg) and CD1 lc (KiM1)
(Bachem Biochemica, Heidelberg, Germany), respec-
tively. MHC class I expression was analyzed using an
anti-human HLA A, B, C monoclonal antibody
(Dako-HLA-ABC, Dako, Hamburg, Germany). Inten-
sity of MHC class II staining was assessed using a
semi-quantitative point score (0 to 3 points for nega-
tive, weak, intermediate and strong staining intensity,
respectively). Staining intensity was expressed as per-
cent of maximal possible score in a given case.
Flow Cytometry
Lymphocytes were immunophenotyped by
three-color FACS analysis on a Becton Dickinson
FACScan flow cytometer using the following mono-
clonal antibodies: isotype controls, anti-CD3,
anti-CD4 (Quantum red labeled) (Sigma, Deisen-
hofen, Germany), anti-CD45RO (unkonjugated),
anti-CD25 (PE-labeled), anti-CD19 (FITC-labeled)
(Dako, Hamburg, Germany), PE-conjugated F(ab’2)
fragment donkey-anti-mouse IgG, anti-HLA-DR
(PE-labeled) (Dianova, Hamburg, Germany),
anti-CD45RA (FITC-labeled) (Coulter Immunotech;288 R STROBEL et al.
Hamburg, Germany) and anti-TCRa[3 (FITC-labeled)
(Becton Dickinson, Heidelberg, Germany).
Semiquantitative RT- PCR
Freshly isolated CD3+4+8 cells from native thymo-
mas, residual thymuses and peripheral blood were
isolated by a combination of depletion/selection pro-
cedures using cell isolation columns (Camon Labor
Service, Wiesbaden, Germany) and immunomagnetic
Beads (Dynal, Hamburg, Germany). The purity of the
isolated subsets was controlled by FACS staining and
was generally > 95 %. Total RNA was prepared from
purified CD4m (106) cells using the RNeasy Kit (Qui-
agen, Hilden, Germany). After cDNA synthesis with
oligo-dT primers and MMLV reverse transcriptase
(Gibco, Eggenstein, Germany), 1/20 of the reaction
was amplified using Taq polymerase (Amersham,
Braunschweig, Germany) and sequence-specific
primers. A semiquantitative PCR was performed by
adjusting all cDNAs to equal amounts of GAPDH
transcripts. The T cell receptorV (TCR V) reper-
toire of a given sample was investigated using a panel
of 24 TCR V[3-specific primers and a fluorescent
TCR Cl3-specific consensus primer as described pre-
viously (Genevee et al. 1992).
Quantitation was performed through digitalization
of ethidium bromide-stained agarose gels and subse-
quent analysis using ONE-Dscan software (Scanalyt-
ics, Billerica, USA). Usage of a single TCR V[
segment was expressed as percentage of the total
product amplified by all the V[3 primers.
Evaluation of CDR3 Length Polymorphisms
Aliqouts of the run-off products were subjected to
electrophoresis using an ABI 373A sequencer
(Applied Biosystems, Weiterstadt, Germany) in the
presence of fluorescent ABI Rox-2500 marker. Evalu-
ation of the CDR3 length polymorphisms was per-
formed using the GenScan software version 1.2.2.
Statistical Procedures And Data Plotting
Analysis of the flow cytometric data and creation of
histograms were performed using the Lysis II soft-
ware (Becton Dickinson). The density of different
surface molecules was determined by using the
median value provided by the software.
For all statistical analyses, data were computed
using the Statistica software (StatSoft, Tulsa, USA)
and tested for significant differences using the
Mann-Whitney-U test (p value < 0.05, unless other-
ways specified).
In this article, thymomas were subtyped according
to the classification proposed by Mtiller-Hermelink et
al. The thymoma subtypes used here correspond to
the new World Health Organization classification,
which distinguishes type A thymomas (medullary),
type AB thymomas (mixed), type B thymomas (sub-
classified as type B 1, predominantly cortical; B2, cor-
tical; and B3, well differentiated thymic carcinomas)
and type C thymomas (thymic carcinomas) (Rosai
and Sobin 1999).
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